At the end of the latest market close, Mereo BioPharma Group plc (MREO) was valued at $4.08. In that particular session, Stock kicked-off at the price of $4.13 while reaching the peak value of $4.14 and lowest value recorded on the day was $3.4501. The stock current value is $3.51.
Recently in News on April 8, 2021, Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference. Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 11:00am Eastern Time. You can read further details here
Mereo BioPharma Group plc had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.71 on 02/22/21, with the lowest value was $2.60 for the same time period, recorded on 01/28/21.
Mereo BioPharma Group plc (MREO) full year performance was 194.96%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Mereo BioPharma Group plc shares are logging -25.50% during the 52-week period from high price, and 240.78% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.03 and $4.71.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2548204 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Mereo BioPharma Group plc (MREO) recorded performance in the market was -1.96%, having the revenues showcasing 0.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 375.25M, as it employees total of 50 workers.
Market experts do have their say about Mereo BioPharma Group plc (MREO)
During the last month, 0 analysts gave the Mereo BioPharma Group plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.25, with a change in the price was noted +1.19. In a similar fashion, Mereo BioPharma Group plc posted a movement of +51.29% for the period of last 100 days, recording 2,859,321 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for MREO is recording 1.64 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.06.
Technical breakdown of Mereo BioPharma Group plc (MREO)
Raw Stochastic average of Mereo BioPharma Group plc in the period of last 50 days is set at 42.83%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 28.69%. In the last 20 days, the company’s Stochastic %K was 58.47% and its Stochastic %D was recorded 65.30%.
Bearing in mind the latest performance of Mereo BioPharma Group plc, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -1.96%. Additionally, trading for the stock in the period of the last six months notably improved by 52.61%, alongside a boost of 194.96% for the period of the last 12 months. The shares increased approximately by -6.40% in the 7-day charts and went up by -15.42% in the period of the last 30 days. Common stock shares were driven by 0.86% during last recorded quarter.